Novo-Nordisk 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Q3 2026 adjusted sales increased 4% to 79.2 billion Danish kroner, driven by GLP-1 volume growth in the U.S. and E.U., primarily in obesity.
- Adjusted operating profit increased 27%, reflecting GLP-1 sales growth and a favorable comparison base after approximately 9 billion Danish kroner of transformation costs in Q3 2025, partly offset by around 3.5 billion Danish kroner of one-time costs in Q3 2026.
- Obesity sales grew 22% in Q3, and Novo reported reaching around 48 million people with its diabetes and obesity treatments, including 5.6 million people receiving obesity treatments.
- Adjusted sales grew 1% in U.S. operations and 8% in international operations; within international operations, UCAN grew 18%.
- Novo reported 8% growth in international GLP-1 sales and 24% growth in international obesity sales, with a GLP-1 volume market share of 54% in international operations.
- In the U.S., Wegovy pill captured around 80% of NBRXs, with more than 8 million cumulative prescriptions since launch; Wegovy pill volumes grew around 20% and injectable Wegovy volumes around 10% sequentially in Q3 versus Q2.
- Ozempic Pill weekly new-to-brand prescriptions more than doubled since launch, and more than 60% of its new-to-brand prescriptions were from people new to GLP-1 treatment.
- In REIMAGINE 5, Kargoxema at 1 milligram of each component demonstrated 12.4% weight loss versus 9.1% for tirzepatide 5 milligrams, with non-inferior HbA1c reduction of around 1.7 percentage points.
- In REDEFINE 9, Kargoxema at 1 milligram of each component demonstrated 21% weight loss at 68 weeks; post-hoc analyses of women in REDEFINE-1 reported average weight loss of 25% overall and 27%, 25%, and 23% in premenopausal, perimenopausal, and postmenopausal groups, respectively.
- A Phase 2 trial of Kargoxema in people with type 2 diabetes and painful diabetic peripheral neuropathy reported a 2.4-point reduction in pain from baseline, approximately 38% reduction in pain, and at least a 30% pain reduction in more than 53% of patients.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and thank you for standing by. Welcome to the Q3 2026 Novo earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star, one, and one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star, one, and one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Michael Novod, Head of Investor Relations.
Please go ahead. Thank you very much, operator.
Welcome to the Novo earnings call for the third quarter of 2026. My name is Michael Novod, and I am the Head of Investor Relations at Novo. With me today, I have CEO Mike Doustdar, EVP U.S. Operations Jamey Millar, EVP International Operations Emil Kongshøj Larsen, EVP Research and Development and Chief Scientific Officer Martin Holst Lange, and Chief Financial Officer Karsten Munk Knudsen. All speakers will be available for the Q&A session. Today's call is being webcast live, and a recording will be made available on our website. The call is scheduled to last one hour. Next slide, please. The presentation is structured as outlined on slide two.
Please stand by while the speakers reconnect. Please stand by while the speakers reconnect.
Do not know where we got disconnected.
Please continue. All right, sorry for that.
We will try to start it from the get-go. On slide three, we need to advise you that this call will contain forward-looking statements. These are subject to risk and uncertainty that could cause actual results to differ materially from expectations. For further information on the risk factors, please see the company announcement for the third quarter of 2026 and the slides prepared for this presentation. With that, over to you, Mike, for an update on our 2030 ambitions.
Thank you very much, Michael. Next slide, please. Back in September, at our Capital Markets Day, we set out our 2030 ambition to deliver mid-single-digit compounded annual sales growth in line with our industry peers from 2026 to 2030. Three commitments drove that ambition. We will grow and diversify our pipeline, we will drive sustainable growth, and we will deliver attractive returns to our shareholders. From this quarter onwards, we will hold ourselves accountable and report progress against each of them. On growing and diversifying our pipeline, we have initiated seven first human dose trials so far this year. In addition, we have 10 ongoing phase III programs. Martin will cover the key pipeline developments about those later on. In terms of driving sustainable growth, we are now reaching around 48 million people with our diabetes and obesity treatments. This is 2 million more than just a year ago.
Especially within obesity, we are treating 5.6 million people, almost doubling during the past 12 months. Obesity sales grew by 22% in quarter three, supported by continued GLP-1 volume growth across geographies, as well as the accelerated rollout of our innovative products, namely Wegovy pill and Wegovy 7.2 milligram, also known as Wegovy HD. In terms of delivering attractive returns, we generated DKK 32 billion in adjusted operating profit and more than DKK 28 billion in free cash flow in Q3 2026. On the back of this strong quarter, we now expect adjusted sales growth of -2% to +2% and adjusted operating profit growth of -2% to +2%, both at CER. Karsten Munk Knudsen will speak to the updated guidance later. Please turn to the next slide. The quarterly development clearly shows that we are at the growth recovery phase, and that is progressing well.
Following adjusted sales decline of 2% in the fourth quarter of 2025 and 4% in the first quarter of 2026, we returned to 7% and 4% growth in the second and the third quarter respectively. Additionally, we are happy to see that this quarter, both operating units are in growth territory again. Behind this is a clear turnaround in patients' volumes. After a flat end to 2025 and a slight decline in the first quarter of 2026, we have now added 1.2 million patients in the second quarter and 1.3 million in the third, which is quite encouraging. What is promising is that growth comes from both obesity and diabetes. In obesity, we have added patients every single quarter, with 0.8 million in Q2 and 0.7 million in Q3. In diabetes, we have moved from losing 0.8 million patients in Q1 to adding 1 million patients in the past two quarters.
In short, more patients are choosing Novo treatments, and we are reaching them across both of our core therapy areas. Next slide, please. In the third quarter, the adjusted sales growth was driven by both operating units. US operations grew 1%, while International Operations grew 8%. Within IO, region EUCAN remained the key growth area, delivering 18% growth. Across therapy areas, obesity continued to be the main growth driver. With that, I will pass it to you, Emil, for a closer look at IO.
Thank you, Mike. Please turn to the next slide. Growth in IO continued to be driven by our GLP-1 portfolio in the third quarter, with total GLP-1 sales increasing by 8%. Obesity remains the key growth driver, delivering 24% growth, supported by continued volume uptake of Wegovy across regions. From a regional perspective, EUCAN was the main growth contributor, with strong performance across both GLP-1 diabetes and obesity. However, performance in Canada was negatively impacted by lower realized prices following the loss of exclusivity for semaglutide. We continue to be the GLP-1 volume leader in IO, with a market share of 54%. We are supporting this position with the rollout of Wegovy pill, Wegovy 7.2 milligram, and Ozempic 2.0 milligram. Please turn to the next slide. We continue to expand our oral obesity leadership across IO.
The pill has now been launched in seven markets, most recently in Mexico, France, Spain, and Poland, and with further launches planned during the fourth quarter. By first half of 2027, we now expect Wegovy pill to be available in more than 20 markets. The market response in the U.K. and UAE is encouraging. While it is early days, we are seeing that Wegovy pill is leading the oral obesity segment with around 90% market share in the U.K. and around 80% market share in the UAE in recent weeks. Six weeks into the launch in Germany, we have also seen solid uptake with approximately 100,000 packs sold, mainly driven by GLP-1-naive patients, which suggests market expansion. While the U.K. market share development is encouraging, we are starting to see a normalization in the uptake, which naturally follows a bolus launch with pent-up demand.
Our focus is now to further build the obesity market. We will do this by driving continued GLP-1-naive patient initiations, supporting patients throughout their treatment journey, ensuring clear switch guidance from injectables, and expanding subscription options that can improve affordability and retention. Overall, these early launches reinforce our confidence that Wegovy pill can reach a broader group of people living with obesity and strengthen our leadership across IO. With that, over to Jamey for an update on the U.S.
Thank you, Emil. Please turn to the next slide. Uptake of the Wegovy pill has continued to outpace the oral competitor in Q3, with Wegovy pill still capturing around 80% of NBRxs. This underpins the strong competitiveness of Wegovy pill. Since launch, we have seen more than 8 million cumulative prescriptions, which remains the strongest U.S. pharma launch by volume in over a decade, outside of vaccines. We see a long runway for the pill in the U.S., with current and incoming initiatives expected to drive more uptake into the new year. In Q3, Wegovy pill volumes grew around 20% versus Q2, and injectable Wegovy volumes grew around 10% sequentially, Q3 versus Q2. Part of the volume growth comes from the Bridge program, where we see encouraging uptake over the last few months. Further, we continue to see the Wegovy franchise leading new-to-brand prescriptions with more than 50% market share.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
18 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
